Zejing pharmaceutical: an advance loss of 372 million yuan to 455 million yuan in 2021
Zejing pharmaceutical announced its annual performance loss forecast for 2021. The company expects a net loss of 372 million yuan to 455 million yuan in 2021. During the reporting period, the company was in the early stage of drug commercialization and needed to invest more in early stage market development and academic promotion activities; At the same time, the company's new drug R & D pipeline is further enriched, and several innovative drugs are in key clinical trials. It is estimated that the R & D cost in 2021 will be about 472 million yuan.
This text is a result of machine translation.
Related companies：
Briefing May 24, 2022 02:24 PM
· Healthcare
Zelensky called on the international community to provide funds for Ukraine's reconstruction, which is expected to cost $500 billion
In-depth
Healthcare
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
Briefing May 21, 2022 06:44 AM
· Financials
913 companies have been investigated by public funds since the second quarter, and the six top flow fund managers focus on the leaders of subdivided industries
Jan 30, 2024 07:59 PM
Dec 11, 2023 08:49 PM
May 11, 2023 05:07 PM
Jan 05, 2023 07:33 PM
Technology
Argentine President Millei backs KIP in advancing AI in Latin America.
Dec 09, 2024 02:43 PM
Briefing Apr 18, 2022 10:18 PM
· Technology
A number of enterprises on the science and innovation board are listed on the "white list" of key enterprises for operation guarantee and transfer
Healthcare
Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab
The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.
Sep 20, 2022 03:35 PM
Briefing Feb 07, 2022 06:49 PM
· Healthcare
Fengtai District of Beijing will lift the epidemic prevention zone of the whole region from now on.
Briefing Jan 14, 2022 02:18 PM
· Healthcare
Hong Kong stocks continued to rise in the anti epidemic sector, and Junshi biology rose nearly 17%
See more
Read next
Insight
In-depth
Insight
In-depth
Consumer Discretionary
Amazon Global Selling: A Decade of Growth in a Vast Market
Dec 17, 2024 05:43 PM
Insight
In-depth
Consumer Staples · Analysis
Din Tai Fung and the Globalization of Chinese Cuisine
Dec 03, 2024 08:26 PM
Insight
In-depth
Communication · Analysis
Podcast Marketing, A Useful Tool for Companies Going Overseas
Dec 02, 2024 02:15 PM